(Mogamulizumab)Biosimilar Reference Antibody-GS40445 新品

货号：GS40445

Mogamulizumab is a humanized, glycoengineered IgG1κ monoclonal antibody that targets CC chemokine receptor 4 (CCR4), a G protein‑coupled receptor expressed on regulatory T cells (Tregs) and Th2 cells. Its Fc region is engineered to enhance antibody‑dependent cellular cytotoxicity (ADCC). By binding to CCR4, mogamulizumab selectively depletes CCR4‑expressing T‑cell subsets, particularly Tregs that suppress anti‑tumor immunity. It is approved for the treatment of mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T‑cell lymphoma (CTCL), in adult patients who have received at least one prior systemic therapy. It is administered via intravenous infusion.